Hydrogen-containing saline alleviates pressure overload-induced interstitial fibrosis and cardiac dysfunction in rats.
Jing Yang, Shujing Wu, Liqun Zhu, Jingjing Cai, Lu Fu · Molecular medicine reports · 2017
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In rats, hydrogen-containing saline (HCS) treatment was observed to improve interstitial fibrosis and cardiac function and to decrease the level of ROS, the oxidative‑stress marker MDA and expression of NOXs, while increasing the activity of the anti‑oxidant enzyme SOD. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in rats. Hydrogen-containing saline (HCS) treatment was observed to improve interstitial fibrosis and cardiac function and to decrease the level of ROS, the oxidative‑stress marker MDA and expression of NOXs, while increasing the activity of the anti‑oxidant enzyme SOD.
What the Researchers Studied
The researchers studied rats. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 16 weeks. Hydrogen-containing saline (HCS) treatment was observed to improve interstitial fibrosis and cardiac function and to decrease the level of ROS, the oxidative‑stress marker MDA and expression of NOXs, while increasing the activity of the anti‑oxidant enzyme SOD. The authors concluded that these results indicate that HCS treatment can improve cardiac function by reducing interstitial fibrosis in pressure‑overloaded rats through its anti‑oxidative properties and via suppression of TGF-β1 signaling. These results indicate that hydrogen inhibits TGF-β1 and its downstream signaling.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The reported sample size was 60. The study used a preclinical animal experiment. The reported treatment duration was 16 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.